Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Socinski

Showing results (51-60 of 279) with videos related to

Pageof 28
Sort By:
Discovery Medicine|September 2, 2016
Immune checkpoint blockade in lung cancerAswin Somasundaram, Mark A Socinski, Liza C Villaruz
Clinical and Translational Medicine|December 16, 2015
KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSaveri Bhattacharya, Mark A Socinski, Timothy F Burns
Expert Opinion on Pharmacotherapy|November 11, 2014
Personalized treatment of EGFR mutant and ALK-positive patients in NSCLCAswin Somasundaram, Mark A Socinski, Timothy F Burns
Drugs|May 22, 2020
Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung CancerAshwin Somasundaram, Mark A Socinski, Liza C Villaruz
The New England Journal of Medicine|September 20, 2018
Atezolizumab Treatment of Nonsquamous NSCLCMartin Reck, Robert M Jotte, Mark A Socinski
Frontiers in Oncology|April 20, 2023
Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicineLiza C Villaruz, Mark A Socinski, Jared Weiss
The Oncologist|November 9, 2016
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at ProgressionMark A Socinski, Liza C Villaruz, Jeffrey Ross
Molecular Diagnosis & Therapy|November 10, 2017
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung CancerKaterina Ancevski Hunter, Mark A Socinski, Liza C Villaruz
Journal of Thoracic Disease|January 10, 2017
Paradoxical functions of ZEB1 in <i>EGFR</i>-mutant lung cancer: tumor suppressor and driver of therapeutic resistanceZachary A Yochum, Mark A Socinski, Timothy F Burns
Oncology (Williston Park, N.Y.)|November 29, 2013
Do oncogenic drivers exist in squamous cell carcinoma of the lung?Liza C Villaruz, Timothy F Burns, Mark A Socinski
Pageof 28

Showing results (51-60 of 279) with videos related to

Sort By:
Pageof 28
Discovery Medicine|September 2, 2016
Immune checkpoint blockade in lung cancerAswin Somasundaram, Mark A Socinski, Liza C Villaruz
Clinical and Translational Medicine|December 16, 2015
KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSaveri Bhattacharya, Mark A Socinski, Timothy F Burns
Expert Opinion on Pharmacotherapy|November 11, 2014
Personalized treatment of EGFR mutant and ALK-positive patients in NSCLCAswin Somasundaram, Mark A Socinski, Timothy F Burns
Drugs|May 22, 2020
Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung CancerAshwin Somasundaram, Mark A Socinski, Liza C Villaruz
The New England Journal of Medicine|September 20, 2018
Atezolizumab Treatment of Nonsquamous NSCLCMartin Reck, Robert M Jotte, Mark A Socinski
Frontiers in Oncology|April 20, 2023
Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicineLiza C Villaruz, Mark A Socinski, Jared Weiss
The Oncologist|November 9, 2016
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at ProgressionMark A Socinski, Liza C Villaruz, Jeffrey Ross
Molecular Diagnosis & Therapy|November 10, 2017
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung CancerKaterina Ancevski Hunter, Mark A Socinski, Liza C Villaruz
Journal of Thoracic Disease|January 10, 2017
Paradoxical functions of ZEB1 in <i>EGFR</i>-mutant lung cancer: tumor suppressor and driver of therapeutic resistanceZachary A Yochum, Mark A Socinski, Timothy F Burns
Oncology (Williston Park, N.Y.)|November 29, 2013
Do oncogenic drivers exist in squamous cell carcinoma of the lung?Liza C Villaruz, Timothy F Burns, Mark A Socinski
Pageof 28